Fluid therapy is essential in ICUs and not surprisingly
there is still much controversy about which fluid to use, how much and when.
Nephrologists often roll their eyes at other subspecialty's preferences, e.g.
surgeon's preferences for Ringers, citing the risk of hyperkalemia in renal
failure patients given Ringers. I learned that normal saline is the preferred
agent unless there is a special consideration such as acidemia necessitating
alternatives. Now chloride, the partner of sodium that gets considerably
less attention most of the time, enters the stage.
Yunos et al in JAMA suggest that too much of chloride
increases acute kidney injury (AKI) episodes in tertiary ICUs and increases the
need for renal replacement therapy (RRT) but does not affect mortality.
The physiological rationale for the detrimental effect of
chloride on the kidney is described as vasoconstriction mediated by chloride in dog experiments and a possible
role of tubuloglomerular feedback mediated vasoconstriction as well as decrease
in GFR caused by increased distal chloride delivery. Furthermore they cite
thromboxane mediated vasoconstriction caused by chloride and enhanced
responsiveness to vasoconstrictor agents as possible physiological sequelae of
chloride administration.
The authors of the JAMA article conducted a prospective, open-label sequential
pilot study of patients admitted consecutively to the ICU. Initially patients
were treated with chloride-rich IV fluids (0.9% saline, 4% succinylated gelatin
solution or 4% albumin solution) and after that initial control period a
chloride-restricted strategy was implemented with lactate (Hartmann solution),
a balanced solution (Plasma-lyte 148) or chloride-poor 20% albumin as preferred
agents.
The results were a lower increase in serum creatinine levels
and fewer episodes of RRT in the chloride-restricted group but no differences
in mortality, hospital or ICU length of stay or need for RRT after discharge.
How does this study affect our choice of ICU fluids?
Certainly, these results are hypothesis generating and important but need to be
viewed as preliminary given the design of the study. An accompanying editorial
by Waikar
mentions the Hawthorne effect as potential major concern. Clearly these important preliminary data need follow up in a
controlled prospective trial.
Posted by Florian Toegel
No comments:
Post a Comment
Renal Fellow Network encourages comments and discussion regarding the posts. Do not post any comments that are commercial or advertising in nature. Posts will be deleted if commercial or advertising comments are made. Internet users commenting on the Renal Fellow Network must post information which is true and correct to their knowledge. Sources to health/medical claims must be provided when relevant. Moderators reserve the right to erase, without notification, any comment they would judge inappropriate.